Could Existing Drugs Already Be Slowing Aging?

Developing a brand-new longevity drug takes decades and billions of dollars. A new study out of Northeastern University and Harvard^[1] asks a cheaper question: what if some of the drugs already sitting in your medicine cabinet are quietly doing anti-aging work we haven’t noticed yet?

Mapping drugs onto the biology of aging

The research, led by network-science researcher Albert-László Barabási, uses a technique called network medicine. Instead of testing drugs directly on aging cells, the team mapped where each drug’s known protein targets sit relative to the “Hallmarks of Aging” — the well-established list of biological breakdowns (DNA instability, cellular miscommunication, and others) that geroscientists use to define aging at the molecular level.

A drug doesn’t have to be designed for aging to matter here. If its target protein sits inside or next to one of these “neighborhoods,” it may be nudging an aging-related pathway as a side effect of treating whatever it was actually approved for.

What they found

The results were mixed, which is honest and useful. Some already-approved drugs showed notable but indirect effects on longevity-related processes. Others hit several aging pathways at once. And some helped in one pathway while creating a drawback in another — a reminder that “affects an aging hallmark” doesn’t automatically mean “safe to take for longevity.”

Why this matters for drug repurposing

The practical value is speed. Every drug on this map has already been through safety trials and regulatory approval for something else. If a network analysis flags one as a strong candidate for slowing an aging pathway, researchers can move straight to testing it for that new purpose — skipping the years of toxicity and dosing work a brand-new molecule requires. That’s the same logic that got metformin and rapamycin onto longevity researchers’ radar in the first place; this study just gives that hunting process a systematic map instead of one drug at a time.

None of this means any specific drug is proven to extend human lifespan — the paper is a discovery tool, not a clinical trial. But it gives researchers a ranked list of where to look next, which is a meaningfully faster starting point than guessing.

Sources

^[1] Barabási, A-L. et al. Network-driven discovery of repurposable drugs targeting hallmarks of aging. Nature Aging, 2026. DOI: 10.1038/s43587-026-01161-8. Finding used: drug-target proximity to Hallmarks-of-Aging disease modules as a repurposing-candidate signal.

Kurt Greiner

Kurt is a digital strategist and IT professional blending emerging technology with practical application to help businesses and individuals streamline their digital presence. His current work focuses on the intersection of intentional living and technological resilience, exploring how individuals can leverage modern tools to navigate the second half of life with purpose.